Second, given that CD44v6 and β-catenin activation are CRC-CIC markers (19, 113) and that FOLFOX therapy induces CD44v6 associated β-catenin-MDR1 signaling (as seen in Figures 2C-G), we examined whether CD44v6-β-catenin signaling can classify CRC/CICs as a FOLFOX-resistant phenotype. This evidence concerns the gene ABCB1 and colorectal carcinoma.